文献速递炎症性肠病

早期启动生物制剂与炎症性肠病结局:全国性队列研究

Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort.
PubMed 文献 · Gastroenterology · 2024-02-06

该研究基于以色列全国IBD研究核心队列(覆盖98%人口,2005-2020年诊断的34,375例患者),采用克隆-删失-逆概率加权方法模拟目标试验,比较不同生物制剂启动时机(0-3个月至>2-3年)与疾病结局的关联。在溃疡性结肠炎中,各启动时机间结肠切除率和类固醇依赖率无显著差异。

要点

  • 克罗恩病极早期启动生物制剂与10年手术风险轻度降低相关(18% vs 31%)。
  • 克罗恩病0-3个月启动者类固醇依赖概率(19%)低于>1年启动者。
  • 溃疡性结肠炎早期启动生物制剂未显著降低结肠切除或类固醇依赖风险。

核心结论

  • 极早期启动生物制剂仅与克罗恩病手术和类固醇依赖风险的轻度降低相关,需未来研究确认。
  • 在溃疡性结肠炎中,早期引入生物制剂未与结肠切除或类固醇依赖风险降低相关。

研究设计与样本

  • 全国性队列研究,纳入以色列2005-2020年诊断的34,375例克罗恩病或溃疡性结肠炎患者(其中儿童5,240例[15%])。
  • 采用克隆、删失和逆概率加权方法模拟目标试验,调整时变混杂和选择偏倚。
  • 比较生物制剂启动时机:0-3个月、>3-12个月、>1-2年、>2-3年。

主要发现

  • 克罗恩病患者中19,264例中7,452例(39%)接受生物制剂;溃疡性结肠炎患者中15,111例中2,235例(15%)接受生物制剂。
  • 克罗恩病0-3个月组与>3-12个月组手术概率无差异。
  • 溃疡性结肠炎各启动时机组间结肠切除率和类固醇依赖率无显著差异;儿童人群趋势相似。

临床怎么用

  • 对于克罗恩病患者,极早期(诊断后0-3个月)启动生物制剂可能轻度降低远期手术和类固醇依赖风险,但需权衡利弊。
  • 对于溃疡性结肠炎患者,早期启动生物制剂未显示降低结肠切除或类固醇依赖风险,决策应个体化。

局限性

  • 观察性研究设计,虽模拟目标试验但可能存在残余混杂。
  • 需未来研究确认克罗恩病中的轻度风险降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In this nationwide study, we explored whether early initiation of biologics is associated with improved outcomes in children and adults with Crohn's disease (CD) and ulcerative colitis (UC). METHODS: All patients diagnosed with CD or UC in Israel (2005-2020) were included in the Epidemiology Group of the Israeli Inflammatory Bowel Disease Research Nucleus cohort, encompassing 98% of the population. We compared disease duration at biologics initiation (ie, 0-3 months, >3-12 months, >1-2 years, and >2-3 years) using the cloning, censoring, and weighting by inverse probabilities method to emulate a target trial, adjusting for time-varying confounders and selection bias. RESULTS: Of the 34,375 included patients (of whom 5240 [15%] were children), 7452 of 19,264 (39%) with CD and 2235 of 15,111 (15%) with UC received biologics. In CD, by 10 years postdiagnosis, the probability of CD-related surgery decreased gradually but modestly with earlier initiation of biologics; a significant difference was noted between >2-3 years (31%) and 0-3 months (18%; P = .02; number needed to treat, 7.7), whereas there was no difference between the 0-3-month and >3-12-month periods. The 10-year probability of steroid dependency for the 0-3-month period (19%) differed both from the >2-3-year (31%; P < .001) and 1-2-year periods (37%; P < .001). In UC, no significant differences in colectomy or steroid dependency rates were observed between the treatment initiation periods. Similar trends were noted in the pediatric population. CONCLUSIONS: Very early initiation of biologics was not associated with some outcomes except for a modest risk reduction of surgery and steroid dependency for CD, which requires confirmation in future studies. In UC, early introduction of biologics was not associated with reduced risk of colectomy or steroid dependency.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Lujan R, Buchuk R, Focht G, et al. Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort. Gastroenterology. 2024. PMID: 38331205. doi:10.1053/j.gastro.2024.01.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。